Claims
- 1. Prostaglandins E represented by a general formula:
- in which X represents: ##STR47## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group;
- R.sub.2 represents: a hydrogen atom or a methyl group;
- R.sub.3 represents: a hydroxyl or hydroxymethyl group;
- R.sub.4 and R.sub.5 each represents: a hydrogen atom, a methyl group, or a halogen atom provided that at least one of R.sub.4 and R.sub.5 is a halogen atom; and
- R.sub.6 represents: C.sub.1 -C.sub.9 alkyl group which may have a branch or a double bond, or C.sub.1 -C.sub.9 alkyl group having an alkoxy substituent group, the C.sub.2 -C.sub.3 bond being a single or double bond.
- 2. Prostaglandins E as described in claim 1, wherein R.sub.4 and R.sub.5 are halogen atoms.
- 3. Prostaglandins E as described in claim 1, wherein R.sub.4 and/or R.sub.5 is a fluorine atom.
- 4. Prostaglandins E as described in claim 1, wherein R.sub.4 or R.sub.5 is a methyl group.
- 5. Prostaglandins E as described in claim 1 having a methyl group on 19 position thereof.
- 6. Prostaglandins E as described in claim 1 wherein R.sub.6 is a hexyl group.
- 7. Prostaglandins E as described in claim 1 wherein R.sub.6 is an isopentyl group.
- 8. Prostaglandins E as described in claim 1 wherein R.sub.6 is a pentyl-2S-group.
- 9. Prostaglandins E as described in claim 1 of which carboxyl group on the terminal position of .alpha.-chain is esterified with alkyl group.
- 10. Prostaglandins E as described in claim 1, which is 13,14-dihydro-15-keto-PGE having one or more fluorine atom on 16-position or alkyl ester thereof.
- 11. Prostaglandins E as described in claim 1 being 13,14-dihydro-15-keto-16R,S-fluoro-PGE.sub.2 or alkyl ester thereof.
- 12. Prostaglandins E as described in claim 1 being 13,14-dihydro-15-keto-16,16-difluoro-PGE.sub.2 or alkyl ester thereof.
- 13. Prostaglandins E as described in claim 1 being 13,14-dihydro-15-keto-16R,S-fluoro-20-methyl-PGE.sub.2 or alkyl ester thereof.
- 14. Prostaglandin E as described in claim 1, wherein R.sub.6 is a C.sub.5 -C.sub.9 alkyl group.
- 15. Prostaglandin E as described in claim 2, wherein each of R.sub.4 and R.sub.5 is a halogen atom.
- 16. Prostaglandin E as described in claim 3, wherein each of R.sub.4 and R.sub.5 is a fluorine atom.
- 17. Prostaglandin E as described in claim 1, wherein only one of R.sub.4 and R.sub.5 is a halogen atom.
- 18. Prostaglandin E as described in claim 17, wherein the halogen atom is a fluorine atom.
- 19. Prostaglandin E as described in claim 1 having a 19-methyl substituent.
- 20. Prostaglandin E as described in claim 1 having a 20-alkyl substituent.
- 21. Prostaglandin E as claimed in claim 1, in the form of a mixture of isomers thereof.
- 22. Prostaglandin E as described in claim 1, wherein the prostaglandin E is 13,14-dihydro-15-keto-16R,S,16R,S-difluoro-PGE.sub.2.
- 23. An anti-ulcer composition comprising an anti-ulcer effective amount of a prostaglandin E expressed by a general formula: ##STR48## in which X represents: ##STR49## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group;
- R.sub.2 represents: a hydrogen atom or a methyl group;
- R.sub.3 represents: a hydroxyl or hydroxymethyl group;
- R.sub.4 and R.sub.5 each represents: a hydrogen atom, a methyl group, or a halogen atom provided that at least one of R.sub.4 and R.sub.5 is a halogen atom; and
- R.sub.6 represents: C.sub.1 -C.sub.9 alkyl group which may have a branch or a double bond, or C.sub.1 -C.sub.9 alkyl group having an alkoxy substituent group, the C.sub.2 -C.sub.3 bond being a single or double bond.
- 24. An antiulcer composition as described in claim 23 wherein R.sub.4 and R.sub.5 are halogen atoms.
- 25. An antiulcer composition as described in claim 23 wherein R.sub.4 and/or R.sub.5 is a fluorine atom.
- 26. An antiulcer composition as described in claim 23 wherein R.sub.4 or R.sub.5 is a methyl group.
- 27. An antiulcer composition as described in claim 23 comprising prostaglandin E of claim 26 having a methyl group on 19-position.
- 28. An antiulcer composition as described in claim 23 wherein R.sub.6 is a hexyl group.
- 29. An antiulcer composition as described in claim 23 wherein R.sub.6 is an isopentyl group.
- 30. An antiulcer composition as described in claim 26 wherein R.sub.6 is a pentyl-2S-group.
- 31. An antiulcer composition as described in claim 23 wherein the prostaglandines E of which carboxyl group on the terminal position of .alpha.-chain is esterified with alkyl group are contained.
- 32. An antiulcer composition as described in claim 23 wherein the prostaglandins E are 13,14-dihydro-15-keto-PGEs having one or more fluorine atom on 16-position or alkyl ester thereof.
- 33. An antiulcer composition as described in claim 23 wherein the prostaglandin E is 13,14-dihydro-15-keto-16R,S-fluoro-PGE.sub.2 or alkyl ester thereof.
- 34. An antiulcer composition as described in claim 23 wherein the prostaglandin E is 13,14-dihydro-15-keto-16,16-difluoro-PGE.sub.2 or alkyl ester thereof.
- 35. An antiulcer composition as described in claim 23 wherein the prostaglandin E is 13,14-dihydro-15-keto-16R,S-fluoro-20methyl-PGE.sub.2 or alkyl ester thereof.
- 36. The anti-ulcer composition of claim 23, wherein the prostaglandin E is in the form of a mixture of isomers thereof.
- 37. The anti-ulcer composition of claim 23, wherein the prostaglandin E is 13,14-dihydro-15-keto-16R,S,16R,S-difluoro-PGE.sub.2.
- 38. A treatment of ulcer by administering an anti-ulcer treating effective amount of prostaglandin E to a patient, wherein the prostaglandin E is represented by a formula: ##STR50## in which X represents: ##STR51## R.sub.1 represents: a hydrogen atom, a physiologically acceptable salt residue, or an ester residue selected from the group consisting of alkyl, benzyl, hydroxyalkyl, alkoxyalkyl, alkylsilyl and tetrahydropyranyl group;
- R.sub.2 represents: a hydrogen atom or a methyl group;
- R.sub.3 represents: a hydroxyl or hydroxymethyl group;
- R.sub.4 and R.sub.5 each represents: a hydrogen atom, a methyl group, or a halogen atom (provided that R.sub.4 and R.sub.5 may be identical with or different from each other); and
- R.sub.6 represents: C.sub.1 -C.sub.9 alkyl group which may have a branch or a double bond, or C.sub.1 -C.sub.9 alkyl group having an alkoxy substituent group, the C.sub.2 -C.sub.3 bond being a single or double bond; except compounds of the formula (I) in which all R.sub.1, R.sub.2, R.sub.4 and R.sub.5 are each hydrogen atoms, R.sub.6 is n-butyl and R.sub.3 is hydroxyl.
Priority Claims (2)
Number |
Date |
Country |
Kind |
62-18820 |
Jan 1987 |
JPX |
|
62-65352 |
Mar 1987 |
JPX |
|
Parent Case Info
This is a Continuation of application Ser. No. 07/406,830 filed Sep. 12, 1989, now abandoned which is a Continuation-in-part of application Ser. No. 07/149,455 filed Jan. 28, 1988, now abandoned.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
3836578 |
Samuelsson |
Sep 1974 |
|
4204074 |
Holland |
May 1980 |
|
Non-Patent Literature Citations (2)
Entry |
Lee et al., "Effects of Oral Administration of PGE.sub.2 . . . Ulcerations", Prostaglandins, Jan. 1973 vol. 3, No. 1, pp. 29-45. |
Anggard, "The Biological Activities of Three Metabolites of Prostaglandin E.sub.1 ", Acta physiol. scand. 1966, 66, pp. 509-510. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
406830 |
Sep 1989 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
149445 |
Jan 1988 |
|